ABSTRACT : This study was performed to investigate the effect of peroxisome proliferators activated receptor-γ (PPAR-γ) ligand, pioglitazone, on production of regulated upon activation normal T-cell expressed and secreted (RANTES) and in vitro fertilization (IVF) outcome in infertile patients with endometriosis. Sixty-four infertile patients with stage III or IV endometriosis undergoing IVF were randomly allocated to the study or the control group. The long protocol of GnRH agonist (GnRH-a) was used for controlled ovarian stimulation (COS) in all patients. Patients in the study group were treated with pioglitazone at a dose of 15 ㎎/day orally from the starting day of GnRH-a treatment to the day of hCG injection.
INTRODUCTION
Regulated upon activation normal T-cell expressed and secreted (RANTES) is a key signaling cytokine involved in initiation of physiologic inflammation (Conti et al., 1999) as well as in many pathologic inflammatory conditions including endometriosis (Oral et al., 1996) . RANTES has been shown to be responsible for 70% of the stimulation of monocyte migration caused by peritoneal fluid from women with endometriosis (Hornung et al., 2001a) . Some authors have suggested that RANTES production might be inhibited by activation of the PPAR pathway. Thia- This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License(http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
zolidinediones including rosiglitazone and pioglitazone are a new class of insulin sensitizers that do not stimulate insulin secretion (Adams et al., 1997) . These drugs act as PPAR-γ agonists, alter gene expression, enhance the sensitivity of tissue to insulin, and partially reverse lipid abnormalities in patients with diabetes (Lenhard, 2001 ).
Therefore, theses drugs have been used for patients with polycystic ovary syndrome (PCOS) undergoing IVF treatment.
Our previous study demonstrated that pioglitazone therapy reduces intraovarian stromal blood flow and is beneficial in improving both the response to ovarian stimulation and IVF outcome in PCOS patients undergoing IVF (Kim et al., 2010) . It has been reported that PPAR-γ also has a beneficial effect on endometriosis. In an in vitro study, PPAR-γ reduced the monocyte migration induced by peritoneal fluid from women with endometriosis (Hornung et al., 2001b) . Therefore, we performed this study to investigate the effect of pioglitazone, a drug of the thiazolidinedione class, on production of RANTES and in vitro fertilization-embryo transfer (IVF-ET) outcomes in infertile patients with stage II or IV endometriosis undergoing IVF treatment.
MATERIAL AND METHODS

Patients
Sixty-four infertile patients with stage III or IV endometriosis who underwent IVF were prospectively recruited to this randomized study, which was performed at the 
Controlled Ovarian Stimulation (COS)
The long protocol of GnRH agonist (GnRH-a) was used for COS in all patients. Daily injection of a GnRH agonist 1 ㎎ (Leuprorelin acetate, Lorelin; Dongkook, Korea) was initiated commencing at the midluteal phase and was continued until menses, followed by a dose reduction to 0.5 ㎎ daily. Ovarian stimulation was started with 50-150 IU of recombinant human follicle-stimulating hormone (rhFSH, Puregon; Organon, Oss, the Netherlands) on menstrual day 3. The initial dose of rhFSH was calculated with reference to patient age and body mass index.
When one or more follicles attained a mean diameter of ≥ 18 ㎜, 250 ㎍ hCG was subcutaneously administered to induce follicular maturation.
In the pioglitazone treatment group, pioglitazone (Actos;
Takeda, Osaka, Japan), 15 ㎎ once daily, was given on the commencement day of GnRH-a administration to the day of human chorionic gonadotropin (hCG, Ovidrel; Serono, Geneva, Switzerland) injection. In the control group, placebo was administered during the same period. Oocytes were retrieved 35-36 hours later, and one to four embryos were transferred to the uterus three days later.
During the luteal phase, 90 ㎎ of vaginal progesterone gel (Crinone 8%; Serono) was applied once daily, starting on the day of oocyte retrieval. Pregnancies were identified by an increase in serum β-hCG concentration and transvaginal ultrasonographic evidence of a gestational sac. Serum concentrations of β-hCG were measured 11 days after embryo transfer (ET) by radioimmunoassay using an hCG MAIA clone kit (Serono Diagnostics, Woking, UK); the inter-and intra-assay variances values were <10% and 5%, respectively. A clinical pregnancy was defined as the presence of a gestational sac on ultrasonography. Blood samples were drawn for serologic assay of RANTES on the day on which the GnRH agonist was first administered and the day of HCG injection. We analyzed serum RANTES concentrations before and after treatment in both groups.
RANTES was measured using a solid-phase enzyme-linked immunosorbent assay (Medgenix Diagnostics, Fleurus, Belgium); interassay and intraassay variances were less than 10% and 5%, respectively..
Statistical analysis
Results are reported as means ± standard deviations (SDs). 
RESULTS
Patients' clinical characteristics and baseline hormone concentrations were similar in the pioglitazone and control groups (Table 1) . Table 2 shows the COS results and 
DISCUSSION
Endometriosis is an inflammatory disease characterized by the presence of endometrial glandular and stromal cells in areas outside of the uterine corpus. The reported disease prevalence varies widely depending on the population studied and the method of sampling employed, the prevalence of endometriosis appears to range from 2% to 18%, whereas within infertile populations the prevalence has been reported to be as high as 50% (Missmer & Cramer, 2003) . Endometriosis is associated with activation of immune cells and aberrant cytokine production in peritoneal fluid, creating a local inflammatory environment (Lebovic et al., 2001; Wu & Ho, 2003) .
In pathologic states including chronic endometritis and endometriosis, inflammation followed by cellular infiltration into the area of interest and is followed by differentiation and activation of immune cells (Pritts et al., 2002) .
Such cells secrete growth factors, cytokines, prostanoids, complement components, and hydrolytic enzymes (Oral et al., 1996) . These signals are released into the bloodstream and chemoattract other immune cells. The levels of cytokines associated with inflammation have been reported to be higher in women with endometriosis (Bedaiwy et al., 2002) as well as in those with unexplained infertility (Demir et al., 2009 ). Both ectopic and eutopic endometrium can be stimulated to produce materials chemoattracting mononuclear cells, including monocyte chemotactic protein-1 (MCP-1) (Arici et al., 1997) , interleukin-8 (IL-8) and RANTES (Khorram et al., 1993) . Many studies have demonstrated abnormal local endometrial production of pro-inflammatory cytokines, such as tumor necrosis factor a (TNF-a), IL-1, IL-6, and IL-8 (Koninckx et al., 1999) . Increasing evidence indicates that RANTES is the key chemokine involved at early stages of the inflammatory process (Appay & Rowland-Jones, 2001 ).
One report showed that RANTES is responsible for 70% of the in vitro monocyte migration activity in peritoneal fluid from women with endometriosis (Hornung et al., 2001 ).
Subsequent activation of cellular inflammatory mediators might be prevented by blocking of early monocyte infiltration.
PPAR plays a key role in the regulation of inflammation and insulin secretion (Yessoufou et al., 2006) . Komar et al. (2001) ovary syndrome (PCOS), but was later reported to be associated with fatal hepatotoxicity (Azziz et al., 2001 ).
This caused the U.S. Food and Drug Administration (FDA) to withdraw approval of the drug. Rosiglitazone, another thiazolidinedione, has also been shown to be effective in inducing ovulation in PCOS patients. Few side-effects are evident in healthy subjects. However, the FDA encourages healthcare professionals to follow current recommendations on the drug label, including a contraindication of rosiglitazone use in patients with NYHA Class III or IV heart failure, and avoidance of use in patients with symptomatic heart failure. All patients should be monitored for signs and symptoms of heart failure (rapid weight gain, difficulty in breathing, and/or swelling) after initiation of treatment and after an increase in dose (Lago et al., 2007; Singh et al., 2007) .
We have shown that administration of pioglitazone reduced the serum concentration of RANTES. Although the response to ovarian stimulation did not improve, the implantation rate was significantly higher in the treatment group. Further, in the pregnant subgroup, RANTES concentration was significantly lower than in the non-pregnant subgroup. Statistically significant differences in RANTES concentrations were evident before and after treatment.
However, However, our study has a limitation to evaluate the efficacy of pioglitazone treatment in endometriosis patients due to a small number of sample available.
Therefore, well-designed larger studies with longer followup times are needed to confirm the effectiveness and safety of pioglitazone.
